Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11963MR)

This product GTTS-WQ11963MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11963MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11659MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ15499MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ2305MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ835MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ15575MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ12852MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ4051MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ10472MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2541546
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW